Reviewer's report
Title:Controlling on demand gastric acidity in obese subjects: a randomized
controlled trial comparing a single dose of rabeprazole 20 mg and omeprazole 20
mg.
Version:2Date:11 February 2014
Reviewer: Manuele Furnari
Reviewer's report:
Belhocine and coworkers, conducted a well designed clinical trial on
asymptomatic and relatively healthy obese subjects to assess and compare the
response of a single oral dose of rabeprazole, omeprazole and placebo. Their
findings showed a good modification of the gastric pH by the two drugs without a
significant difference between them.
The manuscript is clear and well written in all its sections. Discussion and
conclusions are well balance.
However, due to the population setting, the results reported are poorly indicative
and applicable to the clinical practice (obese subjects, without other interacting
medications and comorbidities and especially without gastroesofageal reflux
manifestations). On the other hand, the number of subjects enrolled is low to
obtain reliable information about the pharmacodynamic. Moreover, many studies
demonstrated how the efficacy of PPIs changes even among drugs that share
the same active molecule.
Major revisions
1) Can the author provide more information (in the manuscript or as
supplementary) about the manufacturing of the medications administered to the
subjects? (It is not reported in the Trial registration, too).
2) The author found out that percent of time pH>3/24h was significantly higher on
PPI compared to placebo, but not statistically significant in terms of percent of
time pH>4/24 and median intra-gastric pH was found among the three groups.
The author should further analyse these findings in the discussion sections
(according to the secondary criteria failure of PPIs compare to placebo).
Level of interest: An article of importance in its field
Quality of written English: Acceptable
Statistical review: No, the manuscript does not need to be seen by a statistician.
Reviewer's report
Title:Controlling on demand gastric acidity in obese subjects: a randomized
controlled trial comparing a single dose of rabeprazole 20 mg and omeprazole 20
mg.
Version:2Date:11 February 2014
Reviewer: Manuele Furnari
Reviewer's report:
Belhocine and coworkers, conducted a well designed clinical trial on
asymptomatic and relatively healthy obese subjects to assess and compare the
response of a single oral dose of rabeprazole, omeprazole and placebo. Their
findings showed a good modification of the gastric pH by the two drugs without a
significant difference between them.
The manuscript is clear and well written in all its sections. Discussion and
conclusions are well balance.
However, due to the population setting, the results reported are poorly indicative
and applicable to the clinical practice (obese subjects, without other interacting
medications and comorbidities and especially without gastroesofageal reflux
manifestations). On the other hand, the number of subjects enrolled is low to
obtain reliable information about the pharmacodynamic. Moreover, many studies
demonstrated how the efficacy of PPIs changes even among drugs that share
the same active molecule.
Major revisions
1) Can the author provide more information (in the manuscript or as
supplementary) about the manufacturing of the medications administered to the
subjects? (It is not reported in the Trial registration, too).
2) The author found out that percent of time pH>3/24h was significantly higher on
PPI compared to placebo, but not statistically significant in terms of percent of
time pH>4/24 and median intra-gastric pH was found among the three groups.
The author should further analyse these findings in the discussion sections
(according to the secondary criteria failure of PPIs compare to placebo).
Level of interest: An article of importance in its field
Quality of written English: Acceptable
Statistical review: No, the manuscript does not need to be seen by a statistician.
Please review this paper.
user
Reviewer's report
Title:Controlling on demand gastric acidity in obese subjects: a randomized
controlled trial comparing a single dose of rabeprazole 20 mg and omeprazole 20
mg.
Version:2Date:11 February 2014
Reviewer: Manuele Furnari
Reviewer's report:
Belhocine and coworkers, conducted a well designed clinical trial on
asymptomatic and relatively healthy obese subjects to assess and compare the
response of a single oral dose of rabeprazole, omeprazole and placebo. Their
findings showed a good modification of the gastric pH by the two drugs without a
significant difference between them.
The manuscript is clear and well written in all its sections. Discussion and
conclusions are well balance.
However, due to the population setting, the results reported are poorly indicative
and applicable to the clinical practice (obese subjects, without other interacting
medications and comorbidities and especially without gastroesofageal reflux
manifestations). On the other hand, the number of subjects enrolled is low to
obtain reliable information about the pharmacodynamic. Moreover, many studies
demonstrated how the efficacy of PPIs changes even among drugs that share
the same active molecule.
Major revisions
1) Can the author provide more information (in the manuscript or as
supplementary) about the manufacturing of the medications administered to the
subjects? (It is not reported in the Trial registration, too).
2) The author found out that percent of time pH>3/24h was significantly higher on
PPI compared to placebo, but not statistically significant in terms of percent of
time pH>4/24 and median intra-gastric pH was found among the three groups.
The author should further analyse these findings in the discussion sections
(according to the secondary criteria failure of PPIs compare to placebo).
Level of interest: An article of importance in its field
Quality of written English: Acceptable
Statistical review: No, the manuscript does not need to be seen by a statistician.
assistant